Thermo Fisher Scientific to Release Q3 Earnings Report
The medical technology firm is set to disclose its third quarter financial results on October 21, 2026.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust Wall Street analyst ratings to guide your personal investment decisions?
Thermo Fisher Scientific will release its third quarter earnings report on October 21, 2026. Analysts currently project earnings of $6.40 per share and quarterly revenue of $11.93 billion.
Why it matters
Investors are closely watching these figures as the company expands its reach in the biotech sector through new collaborations. Market analysts have signaled confidence by recently raising price targets for the firm.
Thermo Fisher Scientific shares closed at $679.38 on October 19, 2026. The firm is currently moving forward with a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS.
The players
Thermo Fisher Scientific
This Massachusetts-based supplier of scientific instrumentation and software is a leader in laboratory services.
Quantum BioPharma Ltd.
This company is a biopharmaceutical firm recently partnered with Thermo Fisher to develop new medical treatments.
Morgan Stanley
This global financial services firm provides investment banking, securities, and wealth management services.
TD Cowen
This investment banking division of TD Securities specializes in middle-market companies and research.
Barclays
This British multinational financial services company offers diverse banking and investment research products.
The details
Wall Street sentiment has trended upward, with firms including Morgan Stanley, TD Cowen, and Barclays recently increasing their price targets for the company stock. This financial outlook follows the announcement of a strategic partnership between Thermo Fisher Scientific and Quantum BioPharma Ltd. to advance clinical research.
Timeline
September 3, 2026: CLSA initiated coverage of Thermo Fisher Scientific stock.
September 9, 2026: UBS upgraded the stock to Buy.
October 6, 2026: Quantum BioPharma announced partnership with Thermo Fisher Scientific.
October 7, 2026: Barclays raised price target to $750.
October 21, 2026: Thermo Fisher Scientific releases Q3 earnings report.
The Tech Race
Thermo Fisher Scientific continues to integrate its diagnostic capabilities with experimental drug development in a landscape shaped by the Inflation Reduction Act's Medicare drug-price negotiation provisions. The company faces ongoing competition from other laboratory service providers seeking to capture share in the shifting biopharma R&D market.
For retail investors, these earnings results may trigger volatility in stock prices and influence portfolio allocations for those holding positions in the healthcare sector. Potential changes in the company's research pipeline could also shift the long-term availability of new medical treatments.
The takeaway
Investors should monitor the company's performance against the provided revenue estimates to gauge the success of recent biotech partnerships. Maintaining a balanced perspective on stock target revisions is essential for navigating market volatility in the life sciences sector.
What happens next
Thermo Fisher Scientific will host its Q3 earnings release on October 21, 2026.
Further reading
For broader industry trends, visit the Biotech section on our site.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust Wall Street analyst ratings to guide your personal investment decisions?
